Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25637761 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAHTTPOLBALDH1A1 | |
| SCHEMBL25056210 | 0.85 | HTR1A (0.38) | HTR2AHTR1ADRD2 | |
| SCHEMBL25637686 | 0.85 | SIRT6 (0.34) | SMN1; SMN2LMNAHTTSIRT6POLB | |
| SCHEMBL25637694 | 0.85 | ALDH1A1 (0.38) | SMN1; SMN2LMNASIRT6ALDH1A1CYP2D6 | |
| SCHEMBL25640764 | 0.83 | SIK2 (0.35) | SMN1; SMN2LMNAHTTSIRT6ALDH1A1 | |
| SCHEMBL25637647 | 0.81 | SIRT6 (0.39) | SMN1; SMN2LMNASIRT6ALDH1A1CYP2D6 | |
| SCHEMBL25637849 | 0.81 | SIRT6 (0.38) | SMN1; SMN2LMNASIRT6POLBALDH1A1 | |
| SCHEMBL25056275 | 0.80 | S1PR1 (0.35) | LMNAHTTSIRT6POLBALDH1A1 | |
| SCHEMBL25637842 | 0.79 | KMT2A (0.33) | SMN1; SMN2LMNASIRT6ALDH1A1CYP2D6 | |
| SCHEMBL25637772 | 0.79 | SIRT6 (0.38) | LMNASIRT6POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HTR2A 3774/4885HTR1A 3163/4885DRD2 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.